From, Biotech

From Biotech to Blockchain: 180 Life Sciences Rebrands as ETHZilla

29.01.2026 - 11:23:04 | boerse-global.de

180 Life Sciences US68236V1044

From Biotech to Blockchain: 180 Life Sciences Rebrands as ETHZilla - Foto: über boerse-global.de
From Biotech to Blockchain: 180 Life Sciences Rebrands as ETHZilla - Foto: über boerse-global.de

A significant corporate transformation has been finalized. The company formerly known as 180 Life Sciences has completed a sweeping strategic pivot, emerging under the new corporate identity of ETHZilla Corporation. This rebranding signals a definitive departure from its original biotechnology business model. The firm’s focus is now exclusively centered on managing an Ethereum treasury.

For stakeholders, the primary investment thesis now revolves around the performance of this dedicated Ethereum portfolio. Management’s strategy involves leveraging on-chain yield-generation methods, such as staking and participation in decentralized finance (DeFi) protocols, to create returns. This shift places the company within an expanding trend of publicly-listed entities utilizing digital assets for treasury management.

The move is seen as a gateway to the transparency inherent in blockchain technology and access to yield-bearing opportunities not typically available in traditional finance. However, navigating the inherent volatility of digital assets while maintaining stability through existing liquid resources presents a critical balancing act. ETHZilla’s long-term success will likely depend on its ability to cohesively integrate these distinct asset classes into a unified financial structure.

Should investors sell immediately? Or is it worth buying 180 Life Sciences?

While the core focus has changed, the company retains certain legacy assets. The monetization of its portfolio of biotech patents related to inflammatory diseases continues, though as a secondary consideration. The previously acquired iGaming technology platform also remains part of the company's holdings but is not central to the new strategic direction.

Upcoming Developments and Milestones

Internally, the company is operating under its 2022 Omnibus Incentive Plan. A key provision of this plan is an annual increase in the number of shares available for employee incentives, a mechanism that took effect on January 1, 2026.

For investors seeking concrete updates, the next scheduled events are the routine financial disclosures anticipated for mid-second quarter of 2026. These communications are expected to provide crucial insight into the treasury's performance and the overall liquidity position of ETHZilla Corporation as it charts its new course in the digital asset space.

Ad

180 Life Sciences Stock: Buy or Sell?! New 180 Life Sciences Analysis from January 29 delivers the answer:

The latest 180 Life Sciences figures speak for themselves: Urgent action needed for 180 Life Sciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 29.

180 Life Sciences: Buy or sell? Read more here...

So schätzen die Börsenprofis From Aktien ein!

<b>So schätzen die Börsenprofis From Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
en | US68236V1044 | FROM | boerse | 68530592 |